Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose
NCT ID: NCT04460092
Last Updated: 2020-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2020-05-25
2020-09-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles
NCT00928057
Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units
NCT01334606
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
NCT01231984
Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm.
NCT01745549
Evaluating the Use of Two Different Needles in Subjects With Diabetes
NCT00569426
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After entering the data in SPSS20 software, the collected data will be analyzed using descriptive statistics (frequency, percentage, mean, standard deviation) and statistical tests (t-test, chi-square).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group "A"
In the first three days, participants in group "A" will inject 90-degree insulin injections using 5-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 8 mm to inject insulin.
5-mm 32-gauge Insulin needles in the first three days of Intervention
32-gauge needles with a length of 5mm to inject insulin in first three days
8-mm 32-gauge Insulin needles in the last three days of Intervention
32-gauge needles with a length of 8mm to inject insulin in second three days
Group"B"
In the first three days, participants in group "B" will inject 90-degree insulin injections using 8-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 5mm to inject insulin.
8-mm 32-gauge Insulin needles in the first three days of Intervention
32-gauge needles with a length of 8mm to inject insulin in first three days
5-mm 32-gauge Insulin needles in the last three days of Intervention
32-gauge needles with a length of 5mm to inject insulin in second three days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5-mm 32-gauge Insulin needles in the first three days of Intervention
32-gauge needles with a length of 5mm to inject insulin in first three days
8-mm 32-gauge Insulin needles in the first three days of Intervention
32-gauge needles with a length of 8mm to inject insulin in first three days
5-mm 32-gauge Insulin needles in the last three days of Intervention
32-gauge needles with a length of 5mm to inject insulin in second three days
8-mm 32-gauge Insulin needles in the last three days of Intervention
32-gauge needles with a length of 8mm to inject insulin in second three days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Use injectable insulin for at least two years
* BMI \>18
* Lack of mental illness and mental retardation
* Use insulin pen
Exclusion Criteria
* Having a skin problem in the injection site
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baqiyatallah Medical Sciences University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammad Sadegh Bagheri Baghdasht
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Esmail Heidaranlu
Role: STUDY_CHAIR
Baqiyatallah Medical Sciences University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mohammad Sadegh Bagheri Baghdasht
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mohammad Sadegh Bagheri Baghdasht
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IR.BMSU.BAQ.REC.1398.059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.